Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay

Pediatrics

Volumn 133, Issue 5, 2014, Pages

  Harrington, Rebecca A ^a   Lee, Li Ching ^a   Crum, Rosa M ^b   Zimmerman, Andrew W ^c   Hertz Picciotto, Irva ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Developmental delay; Epidemiology; Pregnancy; Selective serotonin reuptake inhibitors

Indexed keywords

ANXIOLYTIC AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY; ANXIETY DISORDER; ARTICLE; AUTISM; BIRTHPLACE; CELL SIZE; CHILD; CONTROLLED STUDY; DEPRESSION; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG SAFETY; EDUCATIONAL STATUS; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MALE; MENTAL HEALTH; MOOD DISORDER; MOTHER; POPULATION BASED CASE CONTROL STUDY; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUERPERAL DEPRESSION; SELF REPORT; SEX DIFFERENCE; TELEPHONE INTERVIEW; THIRD TRIMESTER PREGNANCY; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; DRUG UTILIZATION; PREGNANCY; PRESCHOOL CHILD; RISK; UNITED STATES;

CALIFORNIA; CASE-CONTROL STUDIES; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; SEX FACTORS;

EID: 84899789470     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3406     Document Type: Article

References (47)

1. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ. 2012;61(3):1-19
2. Mulder EJ, Anderson GM, Kema IP, et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry. 2004;43(4):491-499
3. Whitaker-Azmitia PM. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? Int J Dev Neurosci. 2005; 23(1):75-83
4. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM; National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51(2): 264-270
5. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull. 2001;56(5):479-485
6. Bonnin A, Goeden N, Chen K, et al. A transient placental source of serotonin for the fetal forebrain. Nature. 2011;472(7343): 347-350
7. Dufour-Rainfray D, Vourc'h P, Le Guisquet AM, et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett. 2010;470 (1):55-59
8. Rayen I, van den Hove DL, Prickaerts J, Steinbusch HW, Pawluski JL. Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS ONE. 2011;6(9):e24003
9. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160(5):993-996
10. Cool DR, Liebach FH, Ganapathy V. Interaction of fluoxetine with the human placental serotonin transporter. Biochem Pharmacol. 1990;40(9):2161-2167
11. Anderson GM, Czarkowski K, Ravski N, Epperson CN. Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatr Res. 2004;56(3):418-422
12. Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander TF. Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res. 2011;70(1): 96-101
13. Burstyn I, Wang X, Yasui Y, Sithole F, Zwaigenbaum L. Autism spectrum disorders and fetal hypoxia in a population-based cohort: accounting for missing exposures via Estimation-Maximization algorithm. BMC Med Res Methodol. 2011;11:2
14. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68 (11):1104-1112
15. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346(7907):f2059
16. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406-2415
17. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect. 2006;114(7):1119-1125
18. Rutter M, Le Couteur A, Lord C. Autism Diagnostic Interview-Revised. Los Angeles, CA: Western Psychological Services; 2005
19. Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles, CA: Western Psychological Services; 2007
20. Risi S, Lord C, Gotham K, et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2006; 45(9):1094-1103
21. Rutter M, Bailey A, Lord C. Social Communication Questionnaire. Los Angeles, CA: Western Psychological Services; 2003
22. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales Interview Edition Expanded Form. Circle Pines, MN: American Guidance Service, Inc; 1984
23. Mullen EM. Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service, Inc; 1995
24. Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:128-147
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174
26. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998;18(2):87-123
27. de Souza Silva MA, Mattern C, Topic B, Buddenberg TE, Huston JP. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur Neuropsychopharmacol. 2009;19(1):53-63
28. Weiss LA, Abney M, Cook EH Jr, Ober C. Sexspecific genetic architecture of whole blood serotonin levels. Am J Hum Genet. 2005;76(1):33-41
29. Hohmann CF, Walker EM, Boylan CB, Blue ME. Neonatal serotonin depletion alters behavioral responses to spatial change and novelty. Brain Res. 2007;1139:163-177
30. Lisboa SF, Oliveira PE, Costa LC, Venâncio EJ, Moreira EG. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology. 2007;80(1):49-56
31. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3). Available at: www.pediatrics.org/cgi/content/full/125/3/ e600
32. Jokiranta E, Brown AS, Heinimaa M, Cheslack-Postava K, Suominen A, Sourander A. Parental psychiatric disorders and autism spectrum disorders. Psychiatry Res. 2013;207(3):203-211
33. Larson MJ, Miller K, Fleming KJ. Treatment with antidepressant medications in private health plans. Adm Policy Ment Health. 2007; 34(2):116-126
34. Newport DJ, Brennan PA, Green P, et al. Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentation. BJOG. 2008;115(6): 681-688
35. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011;128(1-2):1-9
36. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402-408
37. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl). 2011;217(2):211-219
38. Rice F, Lewis A, Harold G, et al. Agreement between maternal report and antenatal records for a range of pre and peri-natal factors: the influence of maternal and child characteristics. Early Hum Dev. 2007;83(8): 497-504
39. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. J Psychopharmacol. 1998;12(3 suppl B):S5-S20
40. Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the doseresponse curves of SSRIs. J Psychiatr Pract. 2012;18(1):38-45
41. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42(3):95-100
42. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013;6(3):149-168
43. Velasquez JC, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. Front Cell Neurosci. 2013;7:47
44. Schieve LA, Rice C, Devine O, et al. Have secular changes in perinatal risk factors contributed to the recent autism prevalence increase? Development and application of a mathematical assessment model. Ann Epidemiol. 2011;21(12):930-945
45. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726-735
46. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703-713
47. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115(8):1043-1051